Welcome to BioSeeker Group!

Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis

Additional Information

Published Date Aug 12, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 316
PDF Fact Sheet View Fact Sheet for the report Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis.

    To find out more about Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within breast cancer drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the breast cancer field and identified 148 drug targets belonging to 243 drugs. This report, Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of breast cancer drugs.

In the report, BioSeeker reports on 130 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 243 breast cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and therapy strategy. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of breast drugs. No less than 311 protein-protein interactions were recognized among and between 114 of the 143 included breast cancer drug targets.

Why You Should Own Your Own Copy of this Report:

  • 310+ pages, with more than 60 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
  • A 243 breast cancer drugs analysis, under development by 152 investigators
  • 148 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other breast cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of breast cancer drugs into major therapy strategies
  • Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
  • Pathway profiling of breast cancer drug targets
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition
  • In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 4.1 List of Figures
4.2 List of Tables

5 How to Use this Report

6 Breast Cancer Target Localization

7 The Cancer Genome Project and Breast Cancer Targets
7.1 Breast Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Breast Cancer Drug Targets in Human
8.1 Expression in Normal Tissues and Cancer Tissues
8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Breast Cancer Drugs

10 Protein-Protein Interactions Among Identified Breast Cancer Targets

11 Available Biological Structure Data on Breast Cancer Targets

12 Drug Target Profiles of Breast Cancer Drugs
12.1.1 Catalytic Activity
12.1.2 Cell Adhesion Molecule Activity
12.1.3 Chaperone Activity
12.1.4 Chemokine Activity
12.1.5 Complement Activity
12.1.6 Cysteine-Type Peptidase Activity
12.1.7 Cytokine Activity
12.1.8 DNA Binding
12.1.9 DNA Repair Protein
12.1.10 DNA Topoisomerase Activity
12.1.11 DNA-Directed DNA Polymerase Activity
12.1.12 Glutathione Transferase Activity
12.1.13 G-Protein Coupled Receptor Activity
12.1.14 Growth Factor Activity
12.1.15 Hormone Activity
12.1.16 Kinase Activity
12.1.17 Kinase Binding
12.1.18 Kinase Regulator Activity
12.1.19 Ligand-Dependent Nuclear Receptor Activity
12.1.20 Ligase Activity
12.1.21 Lipid Kinase Activity
12.1.22 Lipid Phosphatase Activity
12.1.23 Metallopeptidase Activity
12.1.24 Molecular Function Unknown
12.1.25 Motor Activity
12.1.26 Oxidoreductase Activity
12.1.27 Protein Binding
12.1.28 Protein Serine/Threonine Kinase Activity
12.1.29 Protein Threonine/Tyrosine Kinase Activity
12.1.30 Protein-Tyrosine Kinase Activity
12.1.31 Receptor Activity
12.1.32 Receptor Binding
12.1.33 Receptor Signaling Complex Scaffold Activity
12.1.34 Receptor Signaling Protein Serine/Threonine Kinase Activity
12.1.35 Serine-Type Peptidase Activity
12.1.36 Structural Constituent of Cytoskeleton
12.1.37 Structural Molecule Activity
12.1.38 Superoxide Dismutase Activity
12.1.39 T Cell Receptor Activity
12.1.40 Transcription Factor Activity
12.1.41 Transcription Regulator Activity
12.1.42 Transferase Activity
12.1.43 Translation Regulator Activity
12.1.44 Transmembrane Receptor Activity
12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity
12.1.46 Transporter Activity

13 The Drug-Target Interactome

14 The Progression and Maturity of Breast Cancer Targets
14.1 Target Profiles of Breast Cancer Drugs in Pre-Registration or on the Market
14.2 New and Unique Breast Cancer Targets in Phase III Clinical Development
14.3 New and Unique Breast Cancer Targets in Phase II Clinical Development
14.4 New and Unique Breast Cancer Targets in Phase I Clinical Development
14.5 New and Unique Breast Cancer Targets in Preclinical Development
14.6 Development Profiles of All Breast Cancer Target Combinations

15 Targets by Major Therapy Strategies in Breast Cancer
15.1 Small Molecules
15.1.1 Background
15.1.2 Targets in Breast Cancer
15.2 Peptide/Protein Drugs
15.2.1 Background
15.2.2 Targets in Breast Cancer
15.3 Monoclonal Antibodies and Antibody-Like Structures
15.3.1 Background
15.3.2 Targets in Breast Cancer
15.4 Nucleic Acid Therapies
15.4.1 Background
15.4.2 Targets in Breast Cancer
15.5 Cell and Gene Therapy
15.5.1 Background
15.5.2 Targets in Breast Cancer
15.6 Drug Delivery and Nanotechnology
15.6.1 Background
15.6.2 Targets in Breast Cancer

16 Breast Cancer Targets by Companies
16.1 Australia
16.2 Austria
16.3 Canada
16.4 China
16.5 Cuba
16.6 Denmark
16.7 Finland
16.8 France
16.9 Germany
16.10 India
16.11 Ireland
16.12 Israel
16.13 Italy
16.14 Japan
16.15 Netherlands
16.16 New Zealand
16.17 Norway
16.18 South Korea
16.19 Sweden
16.20 Switzerland
16.21 United Kingdom
16.22 USA
16.23 Non-Industrial Bodies

17 Disclaimer

18 Drug Index

19 Company Index

4.1 List of Figures
Figure 1: Distribution of Compound Types among Breast Cancer Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
Figure 4: The Drug-Protein Interactome of Breast Cancer Drugs – Main Cluster
Figure 5: The Drug-Protein Interactome of Breast Cancer Drugs – Smaller Clusters
Figure 6: Head-to-Head Targeting Interactome of Breast Cancer Drugs

4.2 List of Tables
Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
Table 3: Drug Targets of Breast Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 4: Available Protein Expression Profiles of Breast Cancer Drug Targets
Table 5: Pathway Summary
Table 6: Drug Targets without any Identified Assigned Pathways
Table 7: Pathway Profile According to BioCarta of Breast Cancer Drug Targets
Table 8: Pathway Profile According to KEGG of Breast Cancer Drug Targets
Table 9: Breast Cancer Drugs Targeting Major Singaling Pathways
Table 10: Protein-Protein Interactions among Breast Cancer Drug Targets
Table 11: Number of Available Biological Structures of Breast Cancer Drug Targets
Table 12: Overview of Drug Target Profile Themes
Table 13: Drug-Protein Interactome Clusters
Table 14: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
Table 15: Top 5 Pursued Breast Cancer Targets
Table 16: Target Profiles of Breast Cancer Drugs in Pre-Registration or on the Market
Table 17: New and Unique Breast Cancer Targets in Phase III Clinical Development
Table 18: New and Unique Breast Cancer Targets in Phase II Clinical Development
Table 19 New and Unique Breast Cancer Targets in Phase I Clinical Development
Table 20: New and Unique Breast Cancer Targets in Preclinical Development
Table 21: The Progression, Maturity and Competitive Comparison of Breast Cancer Drug Targets in Development
Table 22: Number of Breast Cancer Drug Target Mixes Reported by Line of Therapy
Table 23: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Breast Cancer by Drug Target
Table 24: Drug Targets of Small Molecule Drugs in Breast Cancer
Table 25: Mechanistic Relationship between Small Molecule Drugs in Breast Cancer
Table 26: Drug Targets of Peptide Based Drugs in Breast Cancer
Table 27: Drug Targets of Protein Based Drugs in Breast Cancer
Table 28: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Breast Cancer
Table 29: Drug Targets of Nucleic Acid Therapies in Breast Cancer
Table 30: Potential Forms of Cell Therapy
Table 31: Vectors in Gene Therapy
Table 32: Drug Targets of Cell Therapies in Breast Cancer
Table 33: Drug Targets of Gene Therapies in Breast Cancer
Table 34: Drug Targets with New Drug Delivery Strategies in Breast Cancer
Table 35: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Australia
Table 36: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Austria
Table 37: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Canada
Table 38: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in China
Table 39: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Cuba
Table 40: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Denmark
Table 41: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Finland
Table 42: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in France
Table 43: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Germany
Table 44: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in India
Table 45: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Ireland
Table 46: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Israel
Table 47: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Italy
Table 48: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Japan
Table 49: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in the Netherlands
Table 50: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in New Zealand
Table 51: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Norway
Table 52: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in South Korea
Table 53: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
Table 54: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Switzerland
Table 55: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in United Kingdom
Table 56: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in USA
Table 57: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

- Abbott
- Abraxis BioScience
- Access
- Adherex
- Advaxis
- AEgera
- Aeterna Zentaris
- Affibody
- Alchemia
- Algeta
- AlphaVax
- AMDL
- Amgen
- Antisoma
- Aphios
- Apthera
- Ariad
- ARIUS Research
- ArQule
- Array BioPharma
- AstraZeneca
- Attenuon
- AVI BioPharma
- Bayer
- Bionovo
- BioVex
- BiPar Sciences
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Cancer Research Technology
- Cell Therapeutics
- Cel-Sci
- Celsion
- Center of Molecular Immunology
- Cephalon
- ChemGenex Pharmaceuticals
- Chemokine Therapeutics
- Cronos Therapeutics
- Cyclacel
- CytImmune Sciences
- Cytokinetics
- Dabur Pharma
- Dainippon Sumitomo Pharma
- Debiopharm
- Dendreon
- Douglas
- Eisai
- Elan
- Elara Pharmaceuticals
- Eli Lilly
- Enkam Pharmaceuticals
- EntreMed
- Epeius Biotechnologies
- Eucodis
- Exelixis
- Genentech
- Generex
- Genta
- GenVec
- Genzyme
- GlaxoSmithKline
- Heidelberg Pharma
- Hoffmann-La Roche
- Idera Pharmaceuticals
- ImClone Systems
- Immunomedics
- Immunotope
- Immutep
- Incyte Corporation
- Innate Pharma
- Innovive
- Inovio
- Insmed
- Introgen Therapeutics
- Ipsen
- Isis Pharmaceuticals
- Johnson & Johnson
- Karus Therapeutics
- Kosan Biosciences
- Kyowa Hakko
- Ligand
- Lorus Therapeutics
- Meda
- Medarex
- MediGene
- Meiji Seika
- Menarini
- Merck KGaA
- Micromet
- Mologen
- NanoMed Pharmaceuticals
- Nastech
- NeoPharm
- NIH
- Novartis
- Novogen
- OncoGenex Technologies
- Onconova
- Oncothyreon
- Orion Pharma
- OSI Pharmaceuticals
- Oxford BioMedica
- PanaGin
- Pantarhei Bioscience
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacyclics
- PharmaGap
- Pharmexa
- PheneX
- Pro-Pharmaceuticals
- Protherics
- Protox Therapeutics
- PTC Therapeutics
- R&R
- Raptor Pharmaceutical
- Regulon
- Repros Therapeutics
- RESprotect
- Samyang
- Sanofi-Aventis
- Savient Pharmaceuticals
- Schering-Plough
- Semafore Pharmaceuticals
- Sigma-Tau
- Sonus Pharmaceuticals
- SRI International
- SuperGen
- Taiho
- Takeda
- Tapestry Pharmaceuticals
- Targa Therapeutics
- Taxolog
- Telik
- Teva
- Thallion Pharmaceuticals
- Transgene
- Trion Pharma
- University of Pittsburgh
- Vaccinex
- Vion Pharmaceuticals
- VioQuest
- ViRexx
- ViroMed
- ViroTarg
- Wilex
- Wyeth
- Xanthus Pharmaceuticals
- Yakult Honsha
- YM BioSciences
- Zensun

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis.
    To find out more about Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications. Learn More


Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications. Learn More

Other selected research from the 'Oncology' category:


Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update
BioSeeker Group have identified 120 companies plus partners who are today developing 227 immune checkpoints drugs in 835 developmental projects in cancer across 71 different targets. In addition, there are 4 suspended drugs and another 19 drugs where development has been ceased. Learn More


Triple Analysis: Colorectal Cancer, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More